GoodRx cuts guidance

 Guidance

For the third quarter and full year 2024, management is anticipating the following:

$ in millions	3Q 2024	3Q 2023	YoY Change
Revenue1	~$193 - $197	$180.0	~7% - 9%
Adjusted Revenue1	~$193 - $197	$190.0	~2% - 4%
Adjusted EBITDA Margin3	~32%
$ in millions	FY 2024	FY 2023	YoY Change
Revenue1	Low end of our previous ~$800 - $810 range	$750.3	Low end of our previous ~7% - 8% range
Adjusted Revenue1	Low end of our previous ~$800 - $810 range	$760.3	Low end of our previous ~5% - 7% range
Adjusted EBITDA3	>$255

“For the third quarter of 2024, we are guiding to revenue and Adjusted Revenue between $193 million and $197 million and Adjusted EBITDA Margin of about 32%,” said Karsten Voermann, Chief Financial Officer. “For the full year 2024, we expect revenue and Adjusted Revenue to be at the lower end of our previous guidance of $800 million to $810 million. The full year guidance includes approximately $5 million of anticipated impact from Rite Aid’s store closures. For the full year, we expect over $255 million of Adjusted EBITDA, up about 17% from 2023.”

“During the second quarter of 2024, our balance sheet remained robust and we recently successfully refinanced our credit facilities. Our capital allocation priorities are unchanged and we will continue to prioritize high return investments and maximizing value for shareholders,” concluded Voermann.

https://www.businesswire.com/news/home/20240808814959/en